Shares of Lupin Ltd are trading flat after touching a day’s high of Rs 2,004.90 on 26th May, after the company announced signing an agreement with SteinCares for the supply of Ranibizumab in Latin America.

The agreement covers the licensing and supply of biosimilar Ranibizumab in Latin America, excluding Mexico and Argentina.

SteinCares will handle regulatory filings, product registration, and commercialisation across the region.

Lupin will be responsible for manufacturing the biosimilar. Ranibizumab treats several retinal disorders, including AMD, DME, DR, RVO-related Macular Edema, and mCNV.

At 1:46 PM, the shares of Lupin Ltd were trading 0.025% higher at Rs 1,979.40 on NSE.

Lupin Ltd Insights? Let the Analyst Guide You.

Tired of missing hot stocks? Unicorn Signals provides powerful tools like stock scans and more help you make informed trading decisions. Download now and take control of your portfolio!